Nitrendipine in severe hypertension: Satellite symposium on calcium antagonists

Abstract

We report the results of a multicenter trial in which nitrendipine, alone or in combination with a diuretic, a β-blocker, or both, was administered to 114 patients with severe hypertension (≥ 115 mm Hg). Nitrendipine was titrated in doses of 5 to 30 mg b.i.d. If blood pressure was not controlled with nitrendipine alone, hydroehlorothiazide or propranolol or both were added. After a mean of 29 days in the study, 96 (90%) of 107 patients reached the initial goal of therapy; in 44 (41 %) given nitrendipine alone the mean decrease in supine blood pressure was 38/25 mm Hg. After a mean of 91 days, 69 (72%) of 96 patients achieved the final goal of therapy; in 24 (25%) patients given nitrendipine alone the mean supine blood pressure decrease from baseline was 49/33 nun Hg. Falls in blood pressure were comparable in the patients given drug combinations. Seventy-two of 114 patients given study drug(s) had adverse experiences; headache and edema were the most frequent complaints. Only four patients dropped out of the study because of adverse effects. Most abnormal laboratory values occurred when nitrendipine was given with hydroehlorothiazide or propranolol or both. Analysis of severely hypertensive patients followed up in our Virginia center revealed continued control of blood pressure after long-term follow-up (43 ± 3 [SD] months). Average supine blood pressure was reduced from 180/121 ± 21/5 to 140/90 ± 1679 (SD) mm Hg (p < 0.001). It was concluded that the calcium antagonist nitrendipine, alone or in combination with a diuretic or β-blocker or both, is effective in the treatment of severe hypertension. © 1988 American Heart Association, Inc.